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Background: The aim of the this prospective study was to evaluate  the endoscopic ultrasonography 
(EUS) in detecting the cause of common bile duct (CBD) dilatation in patients in whom 
ultrasonography(US) could not indicate  the cause of dilation. 
  
Methods: Seventy patients with the search criteria of unexplained dilated CBD (diameter > 7 mm) 
were examined by EUS. All patients (except 4 patients with pancreatic mass) were further evaluated 
by ERCP. 
  
Results: The following diagnoses were made by EUS and ERCP: choledocholithiasis in 45, 
pancreato-biliary malignancy (PBM) in 17, papillary stenosis in 5, and no finding in 3 cases. We 
found that the majority of patients (95.7%) had findings on EUS to explain the etiology of their 
dilated CBD. The prevalence of pathology is lower (76.9%) in patients with normal liver function 
tests (LFTs).The yield of EUS is higher (100%) when elevated liver enzymes. Lower hemoglobin 
levels, larger diameter of CBD and pancreatic duct (PD) and ESR greater than 30 mm/h were 
independent risk factors for PBM, whereas, patients with previous cholecystectomy, normal LFTs and 
abdominal pain were less likely to have this diagnosis. 
  
Conclusion: the majority of patients referred for EUS for dilated CBD will have an etiology 
discovered 
Therefore, EUS should be the first diagnostic strategy for dilated CBD of unexplained origin, even in 
patients with normal LFTs. In patients with dilated CBD accompanied by anemia, abnormal LFTs and 
ESR or dilated PD, malignancy should be considered. 
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By increasing the use of abdominal 
ultrasonography (US) with nonspecific 
symptoms (such as abdominal 
pain) patients are being diagnosed more 
often with a dilated CBD.
1
The top normal 
value for CBD diameter is controversial 
, which generally accepted to be 7mm. 
2-3
A 
diameter more than 7mm defines as a CBD 
dilatation, which may indicate the presence 
of biliary  pathology 
Precise evaluation of dilated CBD is extremely 
important. Abdominal US is as the imaging 
procedure of choice to 
evaluate these patients with a dilated CBD
4-6
. 
Dilated bile ducts can be reliably demonstrated 
with US, however, the cause can be 
determined in only two thirds of patients.
4-
6
Especially, the distal part of the CBD and the 
papillary region may not be clearly visualized 
on abdominal US. 
ERCP has the highest accuracy for 
the diagnosis of  different imaging 
techniques and is currently considered as a the 
“gold standard” in evaluation of dilated 
CBD.
7
In patients with biliary dilatation, 
clinical index is based on presenting 
symptoms , and liver enzyme profile of serum. 
Indeed, due to the inherent risk associated with 
ERCP, recent guidelines have suggested using 
ERCP as a solely diagnostic tool in cases with 
high probability for therapeutic 
intervention but in a review by Godfrey et al is 
showed that the literature does not clearly 
suggest the best approach to patients with 
asymptomatic or unexplained CBD dilatation 
where MRCP has not been able to determine 
the etiology of CBD dilatation and this 
challenge is the cornerstone of this study while 
apparently cost effectiveness studies should 
also be taken into consideration. When a low 
or moderate clinical suspicion on pathological 
diagnosis is exist, magnetic resonance 
cholangiopancreatography (MRCP) and EUS 
are acceptable as imaging alternatives of 
safety profile for the biliary tract given.
7
 
EUS is an 
excellent procedure for visualizing the biliary 
tract given its proximity when imaging from 
the duodenum.
8,9
 Unlike trans-abdominal US, 
EUS provides excellent sonographic 
visualization of the extra-hepatic biliary tree 
without interference of  bowel gas, because of 
its ability to place the transducer in close 
proximity to the extrahepatic bile duct. 
Additionally, EUS permits accurate and 
systematic visualization of the duodenal wall, 
including the papillary region.
8,9
EUS is 
superior to computed tomography (CT) and 
abdominal US for detection of 
choledocholithiasis and ampullary tumors And 
its accuracy is vividly expressed in 
approaching patients with unexplained CBD 
dilatation which is up to 90%. 
10,11 
  
Based on the cause, biliary dilatation can be 




obstruction may be secondary to any process 
that impairs the passage of bile through the 
biliary tract and into the duodenum. Such 
processes include choledocholithiasis, 
extrinsic compression (e.g. caused by 
Mirizzi’s syndrome or a tumor), sphincter of 
oddi dysfunction (SOD) or papillary stenosis, 
cholangiocarcinoma, pancreatic head mass or 
papillary tumor and parasitic infection. 
Choledocholithiasis is the most common cause 
of obstructive dilatation. The acuity in 
symptom onset can be helpful in narrowing the 
differential diagnosis, because sudden onset 
and pain would be typically associated with 
choledocholithiasis, whereas painless jaundice, 
insidious onset, and weight loss suggest a 
malignant process. Non-obstructive etiologies 
of biliary dilatation include aging, post-
cholecystectomy state and bile duct 
cysts.
12 
The aim of this prospective study was 
to determine the role of EUS in evaluation of 
patients with biliary dilatation and non-
diagnostic sonography findings. 
 
Subjects and Methods 
Seventy four patients were identified from 
November 2013 to September 2014 with the 
search criteria of unexplained dilated CBD. 
Once the patients were identified, their 
electronic records were reviewed for 
demographics, pertinent medical history and 
laboratory data. Patients were considered for 
inclusion in the study if they had CBD dilation 
shown on abdominal US (diameter > 7 mm) 
with unexplained origin. Patients who had a 
clear etiology for their dilated duct(s) (i.e. 
choledolithiasis, pancreatic cancer etc.) and 
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(sphincterotomy or stenting) were excluded 
from the study. 
All patients were examined first with a 
forward-oblique viewing echoendoscope 
(Olympus GF-UM2000, Tokyo, Japan) with a 
radial scan transducer at the tip (5 and 10 MHz 
frequencies). All procedures were performed 
by an expert endosonographist(B.S.) without 
knowledge of the patient’s clinical history, 
laboratory data, or radiologic imaging results. 
70 patients (Except the 4 patients with 
pancreatic mass) was investigated by EUS-
FNA and  ERCP using standard 
duodenoscopes (Olympus TGF-150; Olympus 
Co.).The time interval between EUS and 
ERCP examinations was low than 7 days. The 
endoscopists (T.R.) were blinded to the results 
of the EUS. Four patients were excluded from 
the study due to unsuccessful cannulation of 
CBD. This brought the total number of 
patient’s to70 (43 women and 27 men). 
Overall, the success rate was 100% for EUS 
and 95.7% for ERCP. Two patients had mild 
post-ERCP pancreatitis, and self-limited post-
sphinctrectomy bleeding occurred in 3 
patients. There were no serious complications 
after ERCP and EUS. 
66 cases of 
all patients initially underwent EUS followed 
by ERCP (with or without sphincterotomy) as 
well as 4 cases with pancreatic mass on the 
final diagnosis were confirmed by EUS-
FNA. The diagnosis of papillary stenosis was 
based on the typical biliary pain with or 
without abnormal enzymes suggested on EUS 
as probable papillary stenosis because of 
dilated CBD with distal tapering without any 
other findings and confirmed by ERCP when 
symptoms were relieved completely after 
sphincterotomy. The diagnosis of 
cholangiocarcinoma was confirmed by 
pathologic examination of brushing specimens 
that were obtained during ERCP in one 
patient. In the second patient, ERCP showed a 
distal stricture and pathologic examination 
revealed no malignancy whileCA19-9 was 
above2000 U/mL (without any clinical 
evidence of cholangitis and with normal serum 
IgG4 level). The diagnosis of ampullary 
cancer was confirmed by pathologic 
examination of the biopsy specimens obtained 
by duodenoscope. 
Data were analyzed with a statistical software 
program (SPSS version 18.0, SPSS Inc., 
Chicago, IL). Continuous variables are 
presented as means ± standard deviation (SD) 
and are compared across groups using the one-
way and t-test. Categorical variables are 
expressed as percentages and compared among 
groups using the chi-squared test. Multivariate 
analysis was performed. A p-value of less than 
0.05 was considered significant. The 
institutional review board of our medical 
center approved this study. 
 
Results 
Main characteristics of patients are summarize
-d in table 1.Our study group was composed of 
70 patients in whom US failed to demonstrate 
the cause of dilated CBD. The average age in 
the study was 61.8 years of age (range = 25–
83 years), which the majority were female 
(61.4%). The major presenting symptoms were 
abdominal pain (78.6%), jaundice (35.7%) and 
weight loss (20%). 
EUS and ERCP findings were 
choledocholithiasis in 45 cases, papillary 
stenosis in 5 cases and in 3 cases there 
are no examination findings of symptoms. In 
17 cases, the underlying malignant disease was 
identified by EUS which including, ampullary 
tumor (11 cases), pancreatic tumor (4 cases) 
and distal cholangiocarcinoma (2 cases). 
Furthermore, in 13 patients with normal 
LFTs findings consist of choledocholithiasis (9 
cases), papillary stenosis (1 case) and also, in 
3 cases any finding were no observable. All 
patients had abdominal pain except for 2 
patients, which were asymptomatic with 
normal LFTs and there was no finding. The 
final diagnosis in 57 cases with abnormal 
LFTs included choledolithiasis in 36 cases, 
ampullary cancer in 11 cases, papillary 
stenosis in 4 cases, pancreatic cancer in 4 
cases and cholangiocarcinoma in 2 cases .All 
of the patients with abnormal LFTs were 
symptomatic. 
Four out of five patients with diagnosis of 
papillary stenosis had abnormal LFTs beside 
dilated CBD and considered type 1 SOD. One 
out of five patients had normal LFTs beside 
dilated CBD and underwent ERCP 
sphinctrectomy without previous manometric 
study (because there was no access to this 
study) and this case considered type 2 SOD 
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Indices of diagnostic abdominal 
ultrasonography on 29 patients with 
cholelithiasis demonstrated that the findings 
for dilated CBD were choledocholithiasis in 
24 cases, ampullary cancer in 4 cases, and 
pancreatic cancer in one patient.  Our findings 
in 8 cases with previous cholecystectomy 
included choledocholithiasis in 4, papillary 
stenosis in 3, and no pathology in one patient. 
In three patients with cholecystectomy, 
gallbladder remnant containing’s sludge was 
found, which was missed on abdominal 
ultrasonography.The findings in 3 cases with 
opioid addiction (for more than 5 years) 
included ampullary cancer in 2 and pancreatic 
cancer in one patient. 
A bivariate analysis was performed with two 
groups based on those who had benign 
etiology on EUS and patients withpancreato-
biliary malignant (PBM) etiology for their 
ductal dilatation. There was a statistically 
significant difference in the mean level of 
hemoglobin (Hb), alanine transferase (ALT) 
and bilirubin and mean diameter of pancreatic 
duct (PD) and CBD of patients with a PBM 
compared to those without a PBM(table 2). 
Male gender, presence of jaundice, weight loss 
and ESR greater than 30 mm/h were all 
predictors of PBM on univariate analysis. 
Normal LFTs and presence of abdominal pain 
were negative predictors for PBM on 
univariate analysis. When multivariate 
analysis was performed, the presence of ESR 
greater than 30 mm/h (OR 0.004, 95% CI 0-
0.13), lower levels of Hb (OR 3.04, 95% CI 
1.2-7.7) and larger diameter of CBD (OR 0.67, 
95% CI 0.47-0.96) and PD (OR 0.3, 95% CI 




 Endoscopic ultrasonography as 
an imaging technique is a highly accurate 
and very sensitive modality of imaging the 
biliary system and detecting the cause of CBD 
dilatation. Isolated dilation of CBD is 
unexplained by US is a dilemma for clinicians 
and it is a challenge to decide when further 
evaluation is necessary. 
In the majority of cases, the etiology of dilated 
CBD is benign, however, clinicians are always 






reported that older patients, males and 
those presenting with concurrent elevations in 
the AST/ALT were more likely to have an 
underlying etiology discovered on EUS. 
Moreover, Savio et al.
15
reported that male 
gender, presence of jaundice, abnormal LFTs, 
weight loss, and nonspecific trans abdominal 
imaging results, such as abnormal appearing 
pancreas, predicted the presence of PBM, 
whereas patients with previous 
cholecystectomy and abdominal pain were less 
likely to have this diagnosis. In parallel, in 
agreement with study above we observed 
that lower hemoglobin levels, larger 
diameter of CBD, PD and ESR more than 30 
mm/h were independent risk factors for PBM, 
whereas patients with previous 
cholecystectomy, normal LFTs and abdominal 
pain were less likely to have this 
diagnosis. These findings are comparable to 
those obtained in the a mentioned study.
15
In 
patients with dilated CBD accompany with 
anemia, abnormal LFT and ESR  or dilated 
PD, malignancy should be considered and 
additional imaging is recommended if EUS is 
not diagnostic. 
Furthermore, Yildiran et al.
16
 have revealed 
that EUS provides an accurate explanation for 
CBD dilatation in 70 of the 76 patients 
(92%). In addition, such as report above we 
also have found that the majority of patients 
(95.7%) had findings on EUS to explain the 
etiology of their dilated CBD. Moreover, in 
this study, choledocholithiasis (48 cases) and 
malignancy (17 cases) were the most common 
findings that were comparable to those 





 noted in patients with incidentally 
discovered biliary dilatation, absence of 
clinical signs or symptoms, and normal hepatic 
chemistries, the yields from further 
investigation with EUS and ERCP was low. 
Adrian et al.
12
also proposed that data are 
limited regarding the yield of further 
investigations in patients with incidentally 
identified modest ductal dilatation without 
symptoms or laboratory abnormalities and 
additional investigations are more likely to 
identify clinically relevant findings in patients 
with more pronounced dilatation. Similar to 
previous studies,
13,14 
it was found that patients 
with a dilated CBD and abnormal LFTs were 
more likely to have findings on EUS to 
explain the dilated common bile duct, the yield 
of EUS was 100% in this group. The 
prevalence of pathology was lower (76.9%) in 
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On the other hand, the present study indicated 
the yield of EUS in evaluating biliary 
dilatation is significantly more than previous 
studies, especially in patients with normal 
enzymes. Therefore, it may be logical to 
consider EUS when abdominal US does not 
reveal a cause for CBD dilatation, regardless 
of laboratory findings especially in the 
presence of abdominal pain. We argue against 
the previous concept that further evaluation 
may not be necessary in patients with modest 
CBD dilatation without laboratory 
abnormalities, given the significant prevalence 
of pathology in our findings. However, we 
agree that further evaluation may not be 
necessary in asymptomatic patients with 
normal LFTs. 
 
Limitations of this study 
Our study demonstrated the presence of 
gallstone and opioid addiction can be 
incidental findings and other etiologies (such 
as malignancy) should be considered for their 
ductal dilatation. Although our sample size 
was too small for this conclusion, other 
studies with focus on dilated CBD in the 
presence of gallstone or opioid addiction will 
be helpful. 
In conclusion, we recommend further studies 
with larger sample sizes, especially with a 
focus on asymptomatic patients with 
unexplained dilated CBD and normal 
enzymes. 
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Table 1. Patient characteristics 
 
Characteristicsn(%)  
Cholecystectomy 8 (11.4%) 
Opioid addiction 3 (4.3%) 





female 43 (61.4%) 
Abdominal pain 55 (78.6%) 
Jaundice 25 (35.7%) 
Weight loss 14 (20%) 
 
              
 
 
Table 2. Comparison between patients with and without pancreato-biliary malignancy (PBM) 
 
Characteristics with PBM (n=17) without PBM (n=53) P- value 
Age (years (SD)) 65.6 (± 11.5)             60.5 (±16.1)             0.253 
Male/female                         10/7   17/36                       0.049 
Cholecystectomy 0/8 8/8 0.185     
Abdominal pain 9 (52.9%) 46 (86.8%) 0.003 
Jaundice 12 (70.6%) 13 (24.5%) 0.001 
CBD diameter (mm) 12.2 (± 3.4) 10.1 (± 2.8) 0.012 
PD diameter (mm) 4.4 (± 1.4)              3.2 (± 0.5) 0.002 
Hb (mg/dL) 11.4 (± 1.1) 12.4 (±1.8) 0.015 
ESR > 30 mm/h 13 (76.5%) 4 (7.5%) 0.024 
Normal LFTs 0                       13 (24.5%) 0.024 
AST (IU/L) 92.4 (36-161)         134.1 (10-804)          0.103 
ALT (IU/L)                    85.1 (27-190)        172.4 (7-1353)            0.015 
Alkaline phos. (IU/L) 880.5 (157-2104)         593.5 (19-2826)       0.051 
Bilirubin (mg/dL)            9.6 (0.6-31)             3.9 (0.2-33) 0.004 
 
 
 
  
